2024-09-08 - Analysis Report
## Eli Lilly and Company (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Company (LLY) is a global pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products, including medicines for diabetes, oncology, immunology, and neurology.

**1. Performance Analysis:**

* **Cumulative Returns:** LLY's cumulative return is 528.7%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 81.34%. 
* **Relative Performance:** LLY's current relative performance compared to VOO is 93.09%, indicating it has outperformed VOO by a significant margin over its historical range.

**2. Recent Price Action:**

* **Closing Price:** $902.71
* **5-Day Moving Average:** $935.66
* **20-Day Moving Average:** $933.63
* **60-Day Moving Average:** $893.73

The stock price is currently trading below its 5-day and 20-day moving averages, suggesting a potential short-term downtrend. However, it is above the 60-day moving average, indicating a potential longer-term uptrend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 42.63 
* **PPO (Percentage Price Oscillator):** -0.59
* **Delta_Previous_Relative_Divergence:** -6.22 (Short-term downtrend)
* **Expected Return:** 33.33% (Maximum 5-year expected return on current invested amount)

The RSI suggests the stock is currently in a neutral zone, neither oversold nor overbought. The negative PPO value indicates a downtrend. The negative Delta_Previous_Relative_Divergence also reinforces the short-term downtrend. Despite the recent downtrend, the high expected return suggests potential long-term growth.

**4. Recent Earnings and Outlook:**

| Date         | EPS   | Revenue      |
|--------------|-------|---------------|
| 2024-08-08   | 3.29  | 11.30 B$     |
| 2024-04-30   | 2.49  | 8.77 B$      |
| 2023-11-02   | -0.06 | 9.50 B$      |
| 2023-08-08   | 1.96  | 8.31 B$      |
| 2024-08-08   | 1.96  | 8.31 B$      |

The most recent earnings report for the quarter ending August 2024 showed an EPS of 3.29, exceeding analyst expectations. Revenue also came in strong at 11.30 billion dollars. This positive earnings report suggests strong growth and a positive outlook for the company. 

**5. Overall Analysis:**

LLY has demonstrated strong historical performance, outperforming the S&P 500 significantly. Although recent technical indicators point to a short-term downtrend, its strong earnings report suggests a positive outlook for the future. The high expected return also indicates potential for long-term growth. 

**6. Conclusion:**

While LLY is currently experiencing a short-term correction, its strong fundamentals and positive earnings report suggest a promising long-term growth potential. Investors looking for long-term investments with potential for high returns should consider LLY as a valuable addition to their portfolio. 
